keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis C new treatments

keyword
https://www.readbyqxmd.com/read/28802816/safety-and-efficacy-of-an-8-week-regimen-of-grazoprevir-plus-ruzasvir-plus-uprifosbuvir-compared-with-grazoprevir-plus-elbasvir-plus-uprifosbuvir-in-participants-without-cirrhosis-infected-with-hepatitis-c-virus-genotypes-1-2-or-3-c-crest-1-and-c-crest-2-part
#1
Edward J Gane, Stephen Pianko, Stuart K Roberts, Alexander J Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben-Ari, Graham R Foster, Kosh Agarwal, Alex L Laursen, Jan Gerstoft, Wei Gao, Hsueh-Cheng Huang, Brian Fitzgerald, Doreen Fernsler, Jerry J Li, Anjana Grandhi, Hong Liu, Feng-Hsiu Su, Shuyan Wan, Zhen Zeng, Huei-Ling Chen, Frank J Dutko, Bach-Yen T Nguyen, Janice Wahl, Michael N Robertson, Eliav Barr, Wendy W Yeh, Rebeca M Plank, Joan R Butterton, Rafael Esteban
BACKGROUND: New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed. The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in an 8-week regimen combined with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and to evaluate the safety and tolerability of these combination regimens in individuals infected with genotypes 1, 2, or 3...
August 9, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28801074/rational-heart-transplant-from-hepatitis-c-donor-new-antiviral-weapons-conquer-the-trojan
#2
Robert L Gottlieb, Teena Sam, Suzanne Y Wada, James F Trotter, Sumeet K Asrani, Brian Lima, Susan M Joseph, Gonzalo Gonzalez-Stawinski, Shelley A Hall
BACKGROUND: Donors with hepatitis C (HCV) viremia are rarely utilized for orthotopic heart transplantation (OHTx) due to post-transplant risks. New, highly effective HCV antivirals may alter the landscape. METHODS: An adult patient unsuitable for bridging mechanical support therapy accepted a heart transplant offer from a donor with HCV viremia. Upon daily logarithmic rise in HCV viral load and adequate titers to ensure successful genotyping, once daily sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa) was initiated empirically pending HCV genotype (genotype 3a confirmed after initiation of therapy)...
August 8, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28793934/statin-therapy-causes-gut-dysbiosis-in-mice-through-a-pxr-dependent-mechanism
#3
Jose A Caparrós-Martín, Ricky R Lareu, Joshua P Ramsay, Jörg Peplies, F Jerry Reen, Henrietta A Headlam, Natalie C Ward, Kevin D Croft, Philip Newsholme, Jeffery D Hughes, Fergal O'Gara
BACKGROUND: Statins are a class of therapeutics used to regulate serum cholesterol and reduce the risk of heart disease. Although statins are highly effective in removing cholesterol from the blood, their consumption has been linked to potential adverse effects in some individuals. The most common events associated with statin intolerance are myopathy and increased risk of developing type 2 diabetes mellitus. However, the pathological mechanism through which statins cause these adverse effects is not well understood...
August 9, 2017: Microbiome
https://www.readbyqxmd.com/read/28793069/public-procurement-of-hepatitis-c-medicines-in-brazil-from-2005-to-2015
#4
Gabriela Costa Chaves, Claudia Garcia Serpa Osorio de Castro, Maria Auxiliadora Oliveira
This paper analyzes the Minister of Health's (MoH) procurement of medicines for hepatitis C from 2005 to 2015. Data sources were the Integrated General Services Administration (SIASG), to estimate annual expenditure for selected medicines of the MoH Clinical Protocols and Therapeutic Guidelines (PCDT) for Hepatitis C. All presentations and strengths recorded on SIASG were included. The unit prices were estimated based on the purchase with the highest volume each year. There was a 159.5 fold increase in expenditure of the selected medicines from 2005 to 2006, because procurement of those medicines became centralized...
August 2017: Ciência & Saúde Coletiva
https://www.readbyqxmd.com/read/28782502/society-for-maternal-fetal-medicine-smfm-consult-series-43-hepatitis-c-in-pregnancy-screening-treatment-and-management
#5
Brenna L Hughes, Charlotte M Page, Jeffrey A Kuller
In the United States, 1-2.5% of pregnant women are infected with hepatitis C virus (HCV), which carries an approximately 5% risk of transmission from mother to infant. HCV can be transmitted to the infant in utero or during the peripartum period, and infection during pregnancy is associated with increased risk of adverse fetal outcomes, including fetal growth restriction and low birth weight. The purpose of this document is to discuss the current evidence regarding HCV in pregnancy and to provide recommendations on screening, treatment, and management of this disease during pregnancy...
August 3, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28782340/issues-pertaining-to-daas
#6
Muhammad Umar, Tayyab Saeed Akhter, Muhammad Osama
With the discovery of DAAs, the treatment of hepatitis C has improved a lot. But in this new era of DAAs several issues are also emerging. In this brief communication, we have tried to address the salient issues regarding DAAs.
October 2016: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/28782337/diagnosis-management-and-prevention-of-hepatitis-c-in-pakistan-2017
#7
Muhammad Umar, Hamama-Tul-Bushra Khaar, Tayyab Saeed Akhter, Faiza Aslam, Syed Irfan Ahmad, Rai Mohammad Asghar, Mohammad Khurram, Tassawar Hussain, Amjad Salamat, Anwar A Khan, Fazal-E-Hadi, Zahid Mahmood Minhas, Hasnain Ali Shah, Javed Farooqui, Asif Abbas Naqvi, Aftab Mohsin, Waseem-Ud-Din, Sohail Iqbal Bhutta, Sibt Ul Hasnain Syed, Saleem Qureshi, Tashfeen Adam, Moazzam Uddin, Ghias-U-Nabi Tayyab, Najeeb Ul Haq, Atifa Shoaib, Saima Ambreen, Arslan Shahzad, Nadeem Ikram, Gul Nisar, Mohammad Mujeeb Khan, Mohammad Osama
Aims and Objectives: Since the advent of direct acting antiviral agents, there is a revolutionary change in the management of HCV infection. Newer drugs with different mechanism of action are being introduced and are expected to be available in coming few months in Pakistan as well. The main purpose of the guideline is to review and induct the latest research in field of HCV infection in Pakistani perspective so that our healthcare professionals can apply the new recommendations in timely and judicial manner...
October 2016: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/28776383/hepatocellular-carcinoma-in-patients-without-advanced-fibrosis-after-eradication-of-hcv-with-antiviral-treatment
#8
Yolanda Sánchez-Torrijos, Jara Eloísa Ternero Vega, Carmen Cepeda Franco
From the last few years, hepatitis C virus and the new direct antiviral treatments are being more and more important. In consequence, case studies like the one we present, the appearance of hepatocelullar carcinoma after its eradication with fibrosis grade 2, are getting special interest. In 2007, our patient was treated with pegylated interferon α-2a and ribavirin, having a sustained virological response after it. In this way, liver fibrosis grade 2 was confirmed by a biopsy. Finally, after corroborating a good liver functioning, the patient was discharged (as, according to the guidebooks, an ultrasound scan of screeing every 6 months was not required)...
August 4, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28774800/highlights-of-the-30th-international-conference-on-antiviral-research
#9
Graciela Andrei, Kara Carter, Zlatko Janeba, Aruna Sampath, Luis M Schang, E Bart Tarbet, R Anthony Vere Hodge, Mike Bray, José A Esté
The 30th International Conference on Antiviral Research (ICAR) was held in Atlanta, GA, USA from May 18 to 21, 2017. This report provides an account of award lectures, invited keynote addresses and oral presentations during the meeting. The 2017 Gertrude Elion Memorial Lecture Award by Michael Sofia highlighted one of the most important accomplishments in recent drug discovery in antiviral research, the identification of the hepatitis C virus direct-acting antiviral sofosbuvir and new alternatives to combat hepatitis B virus (HBV) infection...
July 31, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28774417/treatment-of-hepatitis-b-virus-with-combination-therapy-now-and-in-the-future
#10
REVIEW
Joel S Emery, Jordan J Feld
Chronic Hepatitis B continues as a significant public health problem despite the availability of safe and effective antivirals and a highly effective protective vaccine. Current therapy, however rarely leads to cure and lifelong therapy is often required, contributing to poor uptake and ongoing morbidity. New insights into the hepatitis B viral life cycle and the host immune response have expanded the potential targets for drug therapies with interesting antiviral candidates and novel immunotherapeutic approaches in early stage development...
June 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/28774261/modelling-the-burden-of-hepatitis-c-infection-among-people-who-inject-drugs-in-norway-1973-2030
#11
Hinta Meijerink, Richard A White, Astrid Løvlie, Birgitte Freiesleben de Blasio, Olav Dalgard, Ellen J Amundsen, Espen Melum, Hilde Kløvstad
BACKGROUND: Lack of Hepatitis C virus (HCV) incidence data in (Norwegian) high-risk groups impedes the ability to make informed decisions on prevention measures. Thus we rely on modelling to estimate the incidence and burden of HCV infections. METHODS: We constructed a compartmental model for HCV infections in Norway among active and former people who inject drugs (PWIDs). We based yearly transition rates on literature. The model was fitted to absolute numbers of hepatitis C associated cirrhosis, hepatocellular carcinoma (HCC) and death from national data sources (2000-2013)...
August 3, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28774165/current-status-of-hepatitis-c-virus-infection-and-countermeasures-in-south-korea
#12
REVIEW
Sook-Hyang Jeong, Eun Sun Jang, Hwa Young Choi, Kyung-Ah Kim, Wankyo Chung, Moran Ki
Hepatitis C virus (HCV) infection is a major cause of liver cirrhosis, hepatocellular carcinoma, and liver-related mortality. The new antiviral drugs against HCV, direct acting antivirals, result in >90% cure rate. This review aimed to summarize the current prevalence, clinical characteristics, outcomes, and treatment response associated with HCV infection, and countermeasures for optimal HCV control in South Korea. Based on a literature review, the current anti-HCV prevalence in the Korean population is 0...
2017: Epidemiology and Health
https://www.readbyqxmd.com/read/28762691/hiv-associated-complications-a-systems-based-approach
#13
REVIEW
Carolyn Chu, Lealah C Pollock, Peter A Selwyn
Persons with human immunodeficiency virus (HIV) infection often develop complications related directly to the infection, as well as to treatment. Aging, lifestyle factors, and comorbidities increase the risk of developing chronic conditions such as diabetes mellitus and chronic kidney disease. HIV-associated neurologic complications encompass a wide spectrum of pathophysiology and symptomatology. Cardiovascular and pulmonary conditions are common among persons with HIV infection. Although some specific antiretroviral medications have been linked to disease development, traditional risk factors (e...
August 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28762097/a-missense-variant-p-ala117ser-in-the-transthyretin-gene-of-a-han-chinese-family-with-familial-amyloid-polyneuropathy
#14
Qian Chen, Lamei Yuan, Xiong Deng, Zhijian Yang, Shengwang Zhang, Sheng Deng, Hongwei Lu, Hao Deng
Familial amyloid polyneuropathy (FAP) is a dominantly inherited disorder. This study aims to explore the genetic features of a Han Chinese family with FAP, characterized by bloating, alternating diarrhea and constipation, and weakness in his feet. Amyloid presented histologically in the vessel walls of hepatic portal area and nerves of the surgically excised liver specimens from the proband by hematoxylin and eosin staining. Amyloid deposition was further confirmed with Congo red treatment. A c.349G>T transversion (p...
July 31, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28759025/diagnosis-and-severity-criteria-for-sinusoidal-obstruction-syndrome-veno-occlusive-disease-in-pediatric-patients-a-new-classification-from-the-european-society-for-blood-and-marrow-transplantation
#15
S Corbacioglu, E Carreras, M Ansari, A Balduzzi, S Cesaro, J-H Dalle, F Dignan, B Gibson, T Guengoer, B Gruhn, A Lankester, F Locatelli, A Pagliuca, C Peters, P G Richardson, A S Schulz, P Sedlacek, J Stein, K-W Sykora, J Toporski, E Trigoso, K Vetteranta, J Wachowiak, E Wallhult, R Wynn, I Yaniv, A Yesilipek, M Mohty, P Bader
The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of HCT that belongs to a group of diseases increasingly identified as transplant-related, systemic endothelial diseases. In most cases, SOS/VOD resolves within weeks; however, severe SOS/VOD results in multi-organ dysfunction/failure with a mortality rate >80%. A timely diagnosis of SOS/VOD is of critical importance, given the availability of therapeutic options with favorable tolerability...
July 31, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28758018/the-road-to-elimination-of-hepatitis-c-analysis-of-cures-versus-new-infections-in-91-countries
#16
EDITORIAL
Andrew M Hill, Sanjay Nath, Bryony Simmons
BACKGROUND: Hepatitis C (HCV) can only be eradicated if annual rates of cure (SVR) are consistently and significantly higher than new HCV infections, across many countries. In 2016, the WHO called for a 90% reduction in new HCV infection by 2030. Direct-acting antivirals (DAA) can cure the majority of those treated, at around 90% in most populations, at potentially very low prices. We compared the net annual change in epidemic size across 91 countries using data on SVR, new HCV infections, and deaths...
July 1, 2017: Journal of Virus Eradication
https://www.readbyqxmd.com/read/28752960/after-successful-hepatitis-c-virus-antiviral-therapy-it-looks-that-normal-alanine-aminotransferase-level-is-not-the-normal
#17
Mohamed El Kassas, Mohamed Alboraie, Aya Mostafa, Reem Ezzat, Adel El Tahan, Shimaa Afify, Ahmed Sweedy, Ibrahim Kabbash, Gamal Esmat
BACKGROUND: Normal serum alanine aminotransferase (ALT) levels differ with age, gender, and body mass index. Adjusting the upper limits of normal (ULN) for ALT needs further research in different populations. Aim of this work was to monitor the effect of successful chronic hepatitis C (CHC) treatment on the ALT levels in patients with normal pretreatment ALT. METHODS: Data of 1160 CHC patients with persistent pretreatment normal liver enzymes were retrospectively analyzed...
July 28, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/28740342/hepatitis-c-virus-ns5a-region-mutation-in-chronic-hepatitis-c-genotype-1-patients-who-are-non-responders-to-two-or-more-treatments-and-its-relationship-with-response-to-a-new-treatment
#18
Paloma Muñoz de Rueda, José Manuel Fuentes Rodríguez, Rosa Quiles Pérez, Ana Gila Medina, Ana Belén Martín Álvarez, Jorge Casado Ruíz, Angeles Ruíz Extremera, Javier Salmerón
AIM: To determine the number of mutations in the NS5A region of the hepatitis C virus (HCV) and its relationship to the response to antiviral therapy in patients with chronic hepatitis C genotype 1 who are non-responders to two or more treatments. METHODS: Sequences within HCV NS5A [PKR binding domain (PKRBD) and the interferon-sensitivity-determining region (ISDR)] were analysed via direct sequencing in a selected cohort of 72 patients, with a total of 201 treatments [interferon-alpha (IFN-α), n = 49; IFN-α + ribavirin (RBV), n = 75; pegylated (peg) IFN-α + RBV, n = 47; first-generation direct-acting antivirals (DAAs), n = 13; and second-generation DAAs, n = 17]...
July 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28735774/trends-in-hepatitis-c-antibody-prevalence-among-aboriginal-and-torres-strait-islander-people-attending-australian-needle-and-syringe-programs-1996-2015
#19
Simon Graham, Lisa Maher, Handan Wand, Michael Doyle, Jenny Iversen
BACKGROUND: Research indicates that hepatitis C antibody (anti-HCV) prevalence is higher among Australian Aboriginal and Torres Strait Islander (Aboriginal) than non-Aboriginal people who inject drugs (PWID). We examined trends in demographic and drug use characteristics and anti-HCV prevalence among Australian Needle and Syringe Program Survey (ANSPS) respondents by Aboriginal status from 1996 to 2015. METHODS: The ANSPS survey involved collecting demographic, behavioural data and a dried blood spot for anti-HCV testing...
July 20, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28730752/targeted-nanotherapeutics-encapsulating-liver-x-receptor-agonist-gw3965-enhance-antiatherogenic-effects-without-adverse-effects-on-hepatic-lipid-metabolism-in-ldlr-mice
#20
Mikyung Yu, Jaume Amengual, Arjun Menon, Nazila Kamaly, Felix Zhou, Xiaoding Xu, Phei Er Saw, Seung-Joo Lee, Kevin Si, Carleena Angelica Ortega, Won Il Choi, In-Hyun Lee, Yazan Bdour, Jinjun Shi, Morteza Mahmoudi, Sangyong Jon, Edward A Fisher, Omid C Farokhzad
The pharmacological manipulation of liver X receptors (LXRs) has been an attractive therapeutic strategy for atherosclerosis treatment as they control reverse cholesterol transport and inflammatory response. This study presents the development and efficacy of nanoparticles (NPs) incorporating the synthetic LXR agonist GW3965 (GW) in targeting atherosclerotic lesions. Collagen IV (Col IV) targeting ligands are employed to functionalize the NPs to improve targeting to the atherosclerotic plaque, and formulation parameters such as the length of the polyethylene glycol (PEG) coating molecules are systematically optimized...
July 21, 2017: Advanced Healthcare Materials
keyword
keyword
76658
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"